Quoin Pharmaceuticals Ltd.
QYLEKI
Netherton Syndrome
Resolved
14days ago
Approval decision · Jun 23, 2026
What's at stake
A final FDA approval decision on QYLEKI for Netherton Syndrome is expected Jun 23, 2026.
Primary source
· SEC 8-K
verified 15h ago
“On June 23, 2026, the Company announced that the FDA has conditionally approved QYLEKI™ as the proposed brand name for QRX003, the Company’s investigational product candidate for the treatment of Netherton Syndrome.”